Loading briefing details...
Loading briefing details...
News Abstract
By: NewsAbstract Editorial Team
Topic:Business,Health,Science & Environment
May 28, 2026
Creative Biolabs has expanded its lipid-based drug delivery services, targeting researchers developing mRNA, siRNA, protein biologics, vaccines, and gene delivery systems. The updated platform aims to address common challenges in delivering complex therapeutic payloads.
The enhanced services combine custom liposome and lipid nanoparticle (LNP) formulation with comprehensive particle characterization, stability evaluation, and scalable manufacturing support. This approach seeks to overcome issues like payload instability, enzymatic degradation, and inefficient cellular uptake.
Specific LNP formulation services focus on nucleic acid delivery, including mRNA and siRNA, offering optimization for ionizable lipids, microfluidic processes, and particle characteristics. Liposome services are tailored for proteins, peptides, and small molecules, providing lipid composition and surface modification support.
These offerings provide end-to-end support, from initial formulation design through to preclinical development, including analytical characterization and assistance with process scale-up for various therapeutic applications.
The development of advanced therapeutics, such as gene therapies and mRNA vaccines, often faces significant hurdles in effectively delivering active compounds to target cells. Lipid-based systems, like liposomes and lipid nanoparticles, are crucial for protecting sensitive payloads from degradation and ensuring their efficient uptake within the body.
This expansion by Creative Biolabs reflects an ongoing industry focus on refining drug delivery technologies. Improving these systems is essential for translating novel biological discoveries into viable treatments and enhancing the efficacy of next-generation medicines across various therapeutic areas, from oncology to infectious diseases.